481 related articles for article (PubMed ID: 24323898)
1. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
Tan HL; Sood A; Rahimi HA; Wang W; Gupta N; Hicks J; Mosier S; Gocke CD; Epstein JI; Netto GJ; Liu W; Isaacs WB; De Marzo AM; Lotan TL
Clin Cancer Res; 2014 Feb; 20(4):890-903. PubMed ID: 24323898
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing of salivary high-grade neuroendocrine carcinomas identifies alterations in RB1 and the mTOR pathway.
Goyal B; Duncavage EJ; Martinez D; Lewis JS; Chernock RD
Exp Mol Pathol; 2014 Dec; 97(3):572-8. PubMed ID: 25446844
[TBL] [Abstract][Full Text] [Related]
3. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
5. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
Shamir ER; Devine WP; Pekmezci M; Umetsu SE; Krings G; Federman S; Cho SJ; Saunders TA; Jen KY; Bergsland E; Jones K; Kim GE; Kakar S; Chiu CY; Joseph NM
Mod Pathol; 2019 Feb; 32(2):290-305. PubMed ID: 30237525
[TBL] [Abstract][Full Text] [Related]
6. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
[TBL] [Abstract][Full Text] [Related]
7. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.
Morais CL; Herawi M; Toubaji A; Albadine R; Hicks J; Netto GJ; De Marzo AM; Epstein JI; Lotan TL
Prostate; 2015 Oct; 75(14):1610-9. PubMed ID: 26178158
[TBL] [Abstract][Full Text] [Related]
8. Defining triple-negative breast cancer with neuroendocrine differentiation (TNBC-NED).
Hacking SM; Yakirevich E; Wang Y
J Pathol Clin Res; 2023 Jul; 9(4):313-321. PubMed ID: 37082801
[TBL] [Abstract][Full Text] [Related]
9. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
10. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists.
Mohanty SK; Lobo A; Williamson SR; Shah RB; Trpkov K; Varma M; Sirohi D; Aron M; Kandukari SR; Balzer BL; Luthringer DL; Ro J; Osunkoya AO; Desai S; Menon S; Nigam LK; Sardana R; Roy P; Kaushal S; Midha D; Swain M; Ambekar A; Mitra S; Rao V; Soni S; Jain K; Diwaker P; Pattnaik N; Sharma S; Chakrabarti I; Sable M; Jain E; Jain D; Samra S; Vankalakunti M; Mohanty S; Parwani AV; Sancheti S; Kumari N; Jha S; Dixit M; Malik V; Arora S; Munjal G; Gopalan A; Magi-Galluzzi C; Dhillon J
Int J Surg Pathol; 2023 Sep; 31(6):993-1005. PubMed ID: 35946087
[No Abstract] [Full Text] [Related]
11. Establishment and characterization of a novel treatment-related neuroendocrine prostate cancer cell line KUCaP13.
Okasho K; Mizuno K; Fukui T; Lin YY; Kamiyama Y; Sunada T; Li X; Kimura H; Sumiyoshi T; Goto T; Kobayashi T; Lin D; Wang Y; Collins CC; Inoue T; Ogawa O; Akamatsu S
Cancer Sci; 2021 Jul; 112(7):2781-2791. PubMed ID: 33960594
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas.
Tsai H; Morais CL; Alshalalfa M; Tan HL; Haddad Z; Hicks J; Gupta N; Epstein JI; Netto GJ; Isaacs WB; Luo J; Mehra R; Vessella RL; Karnes RJ; Schaeffer EM; Davicioni E; De Marzo AM; Lotan TL
Clin Cancer Res; 2015 Dec; 21(24):5619-29. PubMed ID: 26246306
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488
[TBL] [Abstract][Full Text] [Related]
14. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
Hansel DE; Nakayama M; Luo J; Abukhdeir AM; Park BH; Bieberich CJ; Hicks JL; Eisenberger M; Nelson WG; Mostwin JL; De Marzo AM
Prostate; 2009 May; 69(6):603-9. PubMed ID: 19125417
[TBL] [Abstract][Full Text] [Related]
15. Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas.
Sarkar FH; Sakr W; Li YW; Macoska J; Ball DE; Crissman JD
Prostate; 1992; 21(2):145-52. PubMed ID: 1329054
[TBL] [Abstract][Full Text] [Related]
16. p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.
Li Z; Sun Y; Chen X; Squires J; Nowroozizadeh B; Liang C; Huang J
Mol Cancer Res; 2015 Mar; 13(3):584-91. PubMed ID: 25512615
[TBL] [Abstract][Full Text] [Related]
17. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.
Yachida S; Vakiani E; White CM; Zhong Y; Saunders T; Morgan R; de Wilde RF; Maitra A; Hicks J; Demarzo AM; Shi C; Sharma R; Laheru D; Edil BH; Wolfgang CL; Schulick RD; Hruban RH; Tang LH; Klimstra DS; Iacobuzio-Donahue CA
Am J Surg Pathol; 2012 Feb; 36(2):173-84. PubMed ID: 22251937
[TBL] [Abstract][Full Text] [Related]
18. An in vitro system to characterize prostate cancer progression identified signaling required for self-renewal.
Salah M; Nishimoto Y; Kohno S; Kondoh A; Kitajima S; Muranaka H; Nishiuchi T; Ibrahim A; Yoshida A; Takahashi C
Mol Carcinog; 2016 Dec; 55(12):1974-1989. PubMed ID: 26621780
[TBL] [Abstract][Full Text] [Related]
19. Co-deleting Pten with Rb in retinal progenitor cells in mice results in fully penetrant bilateral retinoblastomas.
Xie C; Lu H; Nomura A; Hanse EA; Forster CL; Parker JB; Linden MA; Karasch C; Hallstrom TC
Mol Cancer; 2015 Apr; 14():93. PubMed ID: 25907958
[TBL] [Abstract][Full Text] [Related]
20. Gene product immunophenotyping of neuroendocrine lung tumors. No linking evidence between carcinoids and small-cell lung carcinomas suggested by multivariate statistical analysis.
Sampietro G; Tomasic G; Collini P; Biganzoli E; Boracchi P; Bidoli P; Pilotti S
Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):49-56. PubMed ID: 10937049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
